Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection against severe COVID-19. The emergence of SARS-CoV-2 variants with heavily mutated spike proteins raises the concern that the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:bioRxiv
Main Authors: Tada, Takuya, Dcosta, Belinda M., Zhou, Hao, Vaill, Ada, Kazmierski, Wes, Landau, Nathaniel R.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7899448/
https://ncbi.nlm.nih.gov/pubmed/33619484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.18.431897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados